Last reviewed · How we verify

Theraworx

John Fowler · FDA-approved active Small molecule ✓ Verified May 2026 Quality 0/100

Theraworx is a Small molecule drug developed by John Fowler. It is currently FDA-approved.

Theraworx has been studied in clinical trials for various conditions, including Surgical Site Infection, Diaper Dermatitis, Urinary Tract Infections, Bacteriuria, and Urinalysis. The product has been tested in interventions such as Chlorhexidine Gluconate 2% Wipe, Theraworx Bath Wipes, and Diaper care with Theraworx.

At a glance

Generic nameTheraworx
SponsorJohn Fowler
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Theraworx

What is Theraworx?

Theraworx is a Small molecule drug developed by John Fowler.

Who makes Theraworx?

Theraworx is developed and marketed by John Fowler (see full John Fowler pipeline at /company/john-fowler).

What development phase is Theraworx in?

Theraworx is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing